Neurocrine Biosciences
NBIX
NBIX
435 hedge funds and large institutions have $8.45B invested in Neurocrine Biosciences in 2022 Q2 according to their latest regulatory filings, with 62 funds opening new positions, 156 increasing their positions, 158 reducing their positions, and 43 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
1% more capital invested
Capital invested by funds: $8.35B → $8.45B (+$99.2M)
1% less repeat investments, than reductions
Existing positions increased: 156 | Existing positions reduced: 158
1.04% less ownership
Funds ownership: 94.85% → 93.81% (-1%)
Holders
435
Holding in Top 10
9
Calls
$111M
Puts
$36.6M
Top Buyers
| 1 | +$67.5M | |
| 2 | +$34.6M | |
| 3 | +$34.1M | |
| 4 |
BlackRock
New York
|
+$31.6M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$30.9M |
Top Sellers
| 1 | -$107M | |
| 2 | -$63.5M | |
| 3 | -$33.4M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$32.4M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$28.1M |